Corrigendum to ‘Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: [Annals of Oncology Volume 31, Issue 6, June 2020, Pages 697-712](S0923753420360798)(10.1016/j.annonc.2020.02.018)

ESMO Guidelines Committee

Research output: Contribution to journalComment/Letter to the editorAcademic

1 Citation (Scopus)

Abstract

The ESMO Guidelines Committee would like to publish a correction to Table S6 in the Supplementary data file originally published in 2020. The authors have added a cautionary comment to a specific dosing recommendation for first-line treatment in newly diagnosed AML patients. 1. Induction and consolidation ChT for patients with CBF-AML, Induction 2 The following text is added: “The doses of cytarabine and daunorubicin recommended here differ from the licensed doses described in the licensing information of GO. Some study groups reduce the dose of daunorubicin or the number of treatment days of daunorubicin.” 4. Standard induction and consolidation ChT with or without GO for patients with ELN favourable (ELN1) or intermediate (ELN2) risk AML, Induction 2 The following text is added: “If GO was used in induction cycle 1: The doses of cytarabine and daunorubicin recommended here differ from the licensed doses described in the licensing information of GO. Some study groups reduce the dose of daunorubicin or the number of treatment days of daunorubicin.”
Original languageEnglish
Pages (from-to)821
Number of pages1
JournalAnnals of Oncology
Volume32
Issue number6
DOIs
Publication statusPublished - 1 Jun 2021

Cite this